PISCATAWAY, N.J.– Camber Pharmaceuticals announced the addition of sapropterin dihydrochloride tablets and powder for oral solution to its current portfolio.
Sapropterin dihydrochloride tablets and powder for oral solution are indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age or older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU).
Sapropterin dihydrochloride tablets are available in 100 mg strength,120 count bottles. Sapropterin dihydrochloride powder for oral solution is available in 100 mg and 500 mg strengths that contain 30 single use packets per carton.
